Old Web
English
Sign In
Acemap
>
authorDetail
>
L. Mi Rim Choi
L. Mi Rim Choi
Medicine
Pegfilgrastim
FOLFIRI
Febrile neutropenia
Clinical endpoint
3
Papers
15
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
A phase II/III study of JZP-458 in patients with acute lymphoblastic leukemia (ALL)/lymphoblastic lymphoma (LBL) who are hypersensitive to E. coli-derived asparaginases.
2020
Journal of Clinical Oncology
Luke Maese
Rachel E. Rau
Elizabeth A. Raetz
Tong Lin
Pil Kim
Reddy Chandula
Sherrie McClung
Julie Gray
L. Mi Rim Choi
Mignon L. Loh
Peter C. Adamson
Show All
Source
Cite
Save
Citations (2)
Results of a phase III, randomized, double-blind, placebo-controlled trial of pegfilgrastim (PEG) in patients (pts) receiving first-line FOLFOX or FOLFIRI and bevacizumab (B) for colorectal cancer (CRC).
2013
Journal of Clinical Oncology
Tamás Pintér
Esteban Abella
Alvydas Česas
Adina E Croitoru
Jochen Decaestecker
Peter Gibbs
Yevhen Hotko
Jacek Jassem
Galina Petrova Kurteva
Jan Novotný
Seamus O’Reilly
T. Šálek
May F. Mo
L. Mi Rim Choi
Charles Davic Blanke
Show All
Source
Cite
Save
Citations (5)
Novel treatment for severe congenital neutropenia with pegfilgrastim
2007
Blood
L. Mi Rim Choi
Christine Guelcher
Michael Guerrera
Show All
Source
Cite
Save
Citations (8)
1